Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Green

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
JAAD International|June 5, 2023
National Psoriasis Foundation Telemedicine Task Force guidance for management of psoriatic disease via telemedicineNatalia Pelet Del Toro, Rayan Yahia, Steven R Feldman, et al.
The Journal of Dermatological Treatment|June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summaryAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
JAMA Dermatology|May 7, 2025
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical TrialMelinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, et al.
Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical TrialAndrew Alexis, Amy McMichael, Jennifer Soung, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
JAAD International|June 5, 2023
National Psoriasis Foundation Telemedicine Task Force guidance for management of psoriatic disease via telemedicineNatalia Pelet Del Toro, Rayan Yahia, Steven R Feldman, et al.
The Journal of Dermatological Treatment|June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summaryAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
JAMA Dermatology|May 7, 2025
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical TrialMelinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, et al.
Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical TrialAndrew Alexis, Amy McMichael, Jennifer Soung, et al.
Pageof 6